Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. We are developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. We recently entered into an exclusive worldwide license and collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, our molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, we have a pipeline of promising early preclinical programs and continues to identify and develop non-nucleoside polymerase inhibitors for norovirus gastroenteritis using our proprietary structure-based drug design technology platform. Source
No articles found.
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
Join the National Investor Network and get the latest information with your interests in mind.